ESTRO/EANO胶质母细胞瘤再程放疗推荐
该ESTRO/EANO指南通过九项关键问题、系统综述及改良DELPHI流程形成18条推荐和9条声明,全部达成共识;其中48%基于前瞻性证据、52%基于专家意见,证据等级未超过中等。推荐再程放疗可考虑用于选定胶质母细胞瘤患者,GTV基于T1加权MRI序列,PTV最大3 mm,生物等效剂量大于36 Gy(2 Gy分次)。
要点
- 再程放疗可考虑用于选定的胶质母细胞瘤患者。
- GTV基于T1加权MRI序列勾画,GTV至CTV外扩非强制。
- PTV最大3 mm,基于个体面罩系统和IGRT流程推荐。
核心结论
- 基于ESTRO/EANO共识,再程放疗可考虑用于选定的胶质母细胞瘤患者。
- 共识推荐和声明涉及患者选择、复发评估影像、靶区勾画、治疗计划、综合治疗和随访等方面。
研究设计与样本
- 本指南为ESTRO/EANO临床实践指南,由放射肿瘤学家、放射学家、肿瘤内科医生、神经肿瘤学家、医学物理师和放射治疗师组成的联合体制定九项关键问题。
- 基于系统综述的证据和专家意见起草推荐和声明,并通过改良DELPHI流程投票。
主要发现
- DELPHI共识流程产生18条推荐和9条声明,全部达成组内共识。
- 13条(48%)基于现有前瞻性证据,14条(52%)基于专家意见。
- 证据等级未超过「中等」,反映大多数再程放疗方面缺乏前瞻性随机证据。
关键数值与推荐
- GTV定义基于T1加权MRI序列,GTV至CTV外扩非强制。
- 基于个体面罩系统和IGRT流程,推荐PTV最大3 mm。
- 推荐生物等效剂量大于36 Gy(2 Gy分次)。
临床怎么用
- 再程放疗可考虑用于选定的胶质母细胞瘤患者(依据ESTRO/EANO共识)。
- 临床推荐需仔细评估影响生存的预后因素,如年龄、初始放疗间隔、大治疗体积、KPS差和神经/神经认知状态差。
局限性
- 证据等级未超过「中等」,反映大多数再程放疗方面缺乏前瞻性随机证据。
- 14条(52%)推荐基于专家意见。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Although reirradiation of glioblastoma has a long history of clinical practice, guidance on how to perform it in the context of recent technological advances, modern imaging modalities or systemic therapy is scarce. This joint ESTRO/EANO guideline aims to collect the existing evidence to produce recommendations for safe reirradiation of glioblastoma. METHODS: The basis of this ESTRO/EANO clinical practice guideline are nine key questions (KQ) which were formulated by a consortium of radiation-oncologists, radiologists, medical oncologists, neurooncologists, medical physicists and radiation therapists. A systematic review was conducted and the KQ were addressed based on this evidence and expert opinion to draft recommendations and statements which were then voted on in a modified DELPHI process. RESULTS: The DELPHI consensus process resulted in 18 recommendations and nine statements of which all achieved group consensus. Thirteen (48%) were based on available prospective evidence and 14 (52%) on expert opinion. Level of evidence did not exceed "moderate", reflecting the scarcity of prospective randomized evidence for most aspects of reirradiation. Consensus recommendations and statements reflected aspects of patient selection, imaging for recurrence assessment, target volume delineation, treatment planning, combined modality treatment, and follow-up. CONCLUSIONS: Currently, based on the ESTRO/EANO consensus, reirradiation may be considered in selected patients with glioblastoma. GTV definition is based on T1-weighted MR-sequences, while a GTV to CTV margin is not mandatory. A PTV margin of maximum 3 mm is recommended based on the individual mask system and IGRT procedures. A biological effective dose greater than 36 Gy in 2 Gy fractions is recommended. A careful assessment of prognostic factors on survival such as age, interval from initial radiation, large treatment volumes, poor KPS, and poor neurologic/neurocognitive status is essential for making a clinical recommendation.
引用
- Andratschke N, Heusel A, Albert NL, et al. ESTRO/EANO recommendation on reirradiation of glioblastoma. Radiother Oncol. 2024. PMID: 42928533. doi:10.1016/j.radonc.2024.110696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。